Your session is about to expire
← Back to Search
Radiopharmaceutical
Quantitative 13N-Ammonia Cardiac Rest/Stress Digital PET/CT
N/A
Waitlist Available
Led By Guido Davidzon, MD, MS
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up an estimated average of 2 hours
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group
Summary
Accurate measurements from a non-invasive test like myocardial perfusion positron emission tomography/ computed tomography (PET/CT) may decrease the need for invasive procedures such as cardiac catheterization.The investigators wish to see if the measurements from cardiac catheterization can be predicted using a non-invasive 13N-NH3 digital PET/CT scan.
Eligible Conditions
- Coronary Artery Disease
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ an estimated average of 2 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~an estimated average of 2 hours
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
CFR measurement using PET/CT
MBF measurement using PET/CT
RFR measurement using PET/CT
Secondary study objectives
Effective radiation dose
NM Physician diagnostic confidence of 13N-NH3 PET/CT
Overall Exam Time
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: N13-ammonia Cardiac Rest/Stress PET/CTExperimental Treatment3 Interventions
Patients with coronary artery disease (CAD) undergo a Cardiac Perfusion Rest/Stress Digital PET/CT scan using the radiopharmaceutical N13-ammonia and Regadenoson (Lexiscan) to induce pharmacologic stress.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Regadenoson
FDA approved
Cardiac Perfusion Rest/Stress Digital PET/CT
2017
N/A
~20
Ammonia
FDA approved
Find a Location
Who is running the clinical trial?
Stanford UniversityLead Sponsor
2,487 Previous Clinical Trials
17,516,728 Total Patients Enrolled
18 Trials studying Coronary Artery Disease
16,960 Patients Enrolled for Coronary Artery Disease
GE HealthcareIndustry Sponsor
302 Previous Clinical Trials
633,903 Total Patients Enrolled
31 Trials studying Coronary Artery Disease
10,163 Patients Enrolled for Coronary Artery Disease
Guido Davidzon, MD, MSPrincipal InvestigatorStanford University